These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 38170343)
1. Upregulation of the canonical signaling pathway of interferon-gamma is associated with glioblastoma progression. Zamora-Salas SX; Macías-Silva M; Tecalco-Cruz AC Mol Biol Rep; 2024 Jan; 51(1):64. PubMed ID: 38170343 [TBL] [Abstract][Full Text] [Related]
2. IFN- Jia H; Xie X; Wang L; Wang L; Che F Comput Intell Neurosci; 2022; 2022():5492602. PubMed ID: 35814563 [TBL] [Abstract][Full Text] [Related]
3. Triptolide reduces PD-L1 through the EGFR and IFN-γ/IRF1 dual signaling pathways. Xie Y; Ding J; Gao J; Zhang J; Cen S; Zhou J Int Immunopharmacol; 2023 May; 118():109993. PubMed ID: 36931170 [TBL] [Abstract][Full Text] [Related]
4. PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer. Zhang X; Zeng Y; Qu Q; Zhu J; Liu Z; Ning W; Zeng H; Zhang N; Du W; Chen C; Huang JA Int J Clin Oncol; 2017 Dec; 22(6):1026-1033. PubMed ID: 28748356 [TBL] [Abstract][Full Text] [Related]
5. IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling. Padmanabhan S; Gaire B; Zou Y; Uddin MM; Vancurova I Cell Signal; 2022 Sep; 97():110400. PubMed ID: 35820543 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-γ treatment. Mimura K; Kua LF; Shiraishi K; Kee Siang L; Shabbir A; Komachi M; Suzuki Y; Nakano T; Yong WP; So J; Kono K Cancer Sci; 2014 Oct; 105(10):1236-44. PubMed ID: 25154680 [TBL] [Abstract][Full Text] [Related]
7. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced Wu B; Song M; Dong Q; Xiang G; Li J; Ma X; Wei F Theranostics; 2022; 12(11):5086-5102. PubMed ID: 35836797 [No Abstract] [Full Text] [Related]
8. Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer. Hänze J; Wegner M; Noessner E; Hofmann R; Hegele A Target Oncol; 2020 Jun; 15(3):377-390. PubMed ID: 32495158 [TBL] [Abstract][Full Text] [Related]
9. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling. Gao Y; Yang J; Cai Y; Fu S; Zhang N; Fu X; Li L Int J Cancer; 2018 Aug; 143(4):931-943. PubMed ID: 29516506 [TBL] [Abstract][Full Text] [Related]
10. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy. Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036 [TBL] [Abstract][Full Text] [Related]
11. Downregulation of CYLD promotes IFN-γ mediated PD-L1 expression in thymic epithelial tumors. Umemura S; Zhu J; Chahine JJ; Kallakury B; Chen V; Kim IK; Zhang YW; Goto K; He Y; Giaccone G Lung Cancer; 2020 Sep; 147():221-228. PubMed ID: 32738418 [TBL] [Abstract][Full Text] [Related]
12. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8 Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272 [TBL] [Abstract][Full Text] [Related]
13. PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ. Iwasa M; Harada T; Oda A; Bat-Erdene A; Teramachi J; Tenshin H; Ashtar M; Oura M; Sogabe K; Udaka K; Fujii S; Nakamura S; Miki H; Kagawa K; Ozaki S; Abe M Oncotarget; 2019 Mar; 10(20):1903-1917. PubMed ID: 30956773 [TBL] [Abstract][Full Text] [Related]
14. Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in Low-Grade Gliomas. Trieu V; Maida AE; Qazi S Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539537 [TBL] [Abstract][Full Text] [Related]
15. Interferon-gamma and tumor necrosis factor-alpha synergistically enhance the immunosuppressive capacity of human umbilical-cord-derived mesenchymal stem cells by increasing PD-L1 expression. Chen Z; Yao MW; Shen ZL; Li SD; Xing W; Guo W; Li Z; Wu XF; Ao LQ; Lu WY; Lian QZ; Xu X; Ao X World J Stem Cells; 2023 Aug; 15(8):787-806. PubMed ID: 37700823 [TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibitors restore the STAT1 pathway and enhance the expression of MHC class I on human colon cancer cells. Liang YH; Chen KH; Tsai JH; Cheng YM; Lee CC; Kao CH; Chan KY; Chen YT; Hsu WL; Yeh KH J Biomed Sci; 2021 Nov; 28(1):75. PubMed ID: 34758826 [TBL] [Abstract][Full Text] [Related]
17. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells. Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036 [TBL] [Abstract][Full Text] [Related]
19. MYC inhibition increases PD-L1 expression induced by IFN-γ in hepatocellular carcinoma cells. Zou J; Zhuang M; Yu X; Li N; Mao R; Wang Z; Wang J; Wang X; Zhou H; Zhang L; Shi Y Mol Immunol; 2018 Sep; 101():203-209. PubMed ID: 30007230 [TBL] [Abstract][Full Text] [Related]
20. Expression of interferon-γ, interferon-α and related genes in individuals with Down syndrome and periodontitis. Tanaka MH; Giro EM; Cavalcante LB; Pires JR; Apponi LH; Valentini SR; Spolidório DM; Capela MV; Rossa C; Scarel-Caminaga RM Cytokine; 2012 Dec; 60(3):875-81. PubMed ID: 22995210 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]